Patient-First Approach Propels Swoop to PM360 Elite 100 Wins

Don’t miss this essential conversation about navigating the complex landscape of healthcare data privacy to make informed marketing strategy decisions .

R&D in rare diseases has skyrocketed. Thirty percent of today’s R&D pipeline is in rare diseases, and 40 percent of overall pipeline growth since 2013 is due to rare diseases.

Health care marketing is rapidly evolving, driven by AI, health privacy legislation, the need to reach more diverse patient communities, and the growth of direct-to-patient offerings. To help us sort the reality from the hype, we invited four brilliant partners from top pharma agencies to join a panel at our recent MyHealthTeam Summer Summit in NYC. Their candid, unfiltered observations are summarized below.

I believe in the power of data-driven omnichannel strategies, but so many in our industry don’t understand what matters: Connecting with the right audiences on the right channels.

Every year at Digital Pharma East, the industry comes together to connect and learn from each other. Here’s everything you need to know from DPE 2024. 

From gathering real-time data to inform marketing strategies to improving the overall patient experience, AI-powered virtual agents can help personalize customer interactions.

Pharmaceutical brands can proactively engage patients and providers using predictive AI to engage audiences based on what will likely happen

At MyHealthTeam’s all-company get-together in Nashville, we invited five pharma marketing experts from top agencies and biotechs to join me on a panel. We discussed the “New Marketing Playbook” for everything from rare disease launches to direct-to-patient models to innovative uses of AI with patients.

“The Reuters Pharma USA conference, held this spring in Philadelphia, is one of the best conferences attended by and featuring pharma executives. Here are our notes on some of the top themes and actionable takeaways from the event.”

“Data is not created equally. Understanding the difference between zero-party and first-party data can be game-changing for pharma marketers. Below is a guide on how pharma marketers can reach more of the right people with less waste.”